Friday, 2 December 2016

Market Overview on Chronic Myelocytic Leukemia - Pipeline Review, H2 2016

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.
Report Highlights
This report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 27, 24, 24, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 5, 8 and 3 molecules, respectively.Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia).
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc Altor BioScience Corp arGEN-X BV Ariad Pharmaceuticals Inc Array BioPharma Inc Ascentage Pharma Group Corp Ltd Astex Pharmaceuticals Inc Atara Biotherapeutics Inc Bellicum Pharmaceuticals Inc Bio-Path Holdings Inc Biogenomics Limited BioLineRx Ltd BioSight Ltd Boston Biomedical Inc Bristol-Myers Squibb Company Cantargia AB Celgene Corp Cellectar Biosciences Inc Cielo Therapeutics Inc Constellation Pharmaceuticals Inc CSPC Pharmaceutical Group Limited Daiichi Sankyo Company Ltd Deciphera Pharmaceuticals LLC Eisai Co Ltd EpiZyme Inc F. Hoffmann-La Roche Ltd Galena Biopharma Inc Gamida Cell Ltd GlycoMimetics Inc HEC Pharm Co., Ltd. Hovione FarmaCiencia SA Hybrigenics SA Ilyang Pharmaceutical Co Ltd Incyte Corp Jiangsu Hansoh Pharmaceutical Co Ltd Johnson & Johnson Juno Therapeutics Inc JW Pharmaceutical Corp Karyopharm Therapeutics Inc Lixte Biotechnology Holdings Inc Mesoblast Ltd Natco Pharma Ltd Novartis AG OncoTherapy Science Inc Ono Pharmaceutical Co Ltd Oribase Pharma Panther Biotechnology, Inc. Pfizer Inc Pharma Mar SA PharmaEssentia Corp Sellas Inc Selvita SA Shenogen Pharma Group Ltd Shire Plc SignalChem Lifesciences Corp Stemline Therapeutics Inc Sun Pharma Advanced Research Company Ltd Syndax Pharmaceuticals Inc Takeda Pharmaceutical Company Ltd Targazyme Inc Teva Pharmaceutical Industries Ltd TRACON Pharmaceuticals Inc Tragara Pharmaceuticals Inc VioQuest Pharmaceuticals Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

0 Comments:

Post a Comment

Subscribe to Post Comments [Atom]

<< Home